Ftse Mib
35.355,87
0,58%
DAX
18.869,36
0,78%
S&P 500
5.302,36
1,06%
NASDAQ
16.739,07
1,38%
Bitcoin
65.936,14
7,13%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Enveric Biosciences Inc (ENVB) Enveric Biosciences Inc (ENVB) Notizie

ENVB

Enveric Biosciences (ENVB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ENVB
DataOraFonteTitoloSimboloCompagnia
15/05/202412:00Business WireEnveric Biosciences Reports First Quarter 2024 Financial and Corporate ResultsNASDAQ:ENVBEnveric Biosciences Inc
14/05/202414:00Business WireEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health DisordersNASDAQ:ENVBEnveric Biosciences Inc
08/05/202413:00Business WireEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using CannabinoidsNASDAQ:ENVBEnveric Biosciences Inc
26/03/202412:00Business WireEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023NASDAQ:ENVBEnveric Biosciences Inc
19/03/202412:00Business WireEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint DiseaseNASDAQ:ENVBEnveric Biosciences Inc
12/03/202412:00Business WireEnveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term SheetsNASDAQ:ENVBEnveric Biosciences Inc
11/03/202417:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ENVBEnveric Biosciences Inc
11/03/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENVBEnveric Biosciences Inc
29/02/202413:00Business WireEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of CompoundsNASDAQ:ENVBEnveric Biosciences Inc
26/02/202422:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENVBEnveric Biosciences Inc
23/02/202414:00Business WireEnveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual PropertyNASDAQ:ENVBEnveric Biosciences Inc
21/02/202414:00Business WireEnveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersNASDAQ:ENVBEnveric Biosciences Inc
14/02/202421:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENVBEnveric Biosciences Inc
06/02/202416:17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ENVBEnveric Biosciences Inc
24/01/202414:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENVBEnveric Biosciences Inc
23/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENVBEnveric Biosciences Inc
11/01/202422:43Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENVBEnveric Biosciences Inc
29/12/202314:52Business WireEnveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-MarketNASDAQ:ENVBEnveric Biosciences Inc
28/12/202314:00Business WireEnveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 SeriesNASDAQ:ENVBEnveric Biosciences Inc
27/12/202314:00Business WireEnveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373NASDAQ:ENVBEnveric Biosciences Inc
20/12/202314:00Business WireEnveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”NASDAQ:ENVBEnveric Biosciences Inc
06/12/202322:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ENVBEnveric Biosciences Inc
05/12/202314:00Business WireEnveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsNASDAQ:ENVBEnveric Biosciences Inc
01/12/202322:31Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ENVBEnveric Biosciences Inc
29/11/202314:00Business WireEnveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin DerivativesNASDAQ:ENVBEnveric Biosciences Inc
27/11/202314:00Business WireEnveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal ChemistryNASDAQ:ENVBEnveric Biosciences Inc
24/11/202314:00Business WireEnveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)NASDAQ:ENVBEnveric Biosciences Inc
13/11/202322:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENVBEnveric Biosciences Inc
13/11/202322:01Business WireEnveric Biosciences Reports Third Quarter 2023 Corporate and Financial ResultsNASDAQ:ENVBEnveric Biosciences Inc
31/10/202313:00Business WireEnveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of PsilocinNASDAQ:ENVBEnveric Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ENVB

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
BPE
Bper Banca
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BAMI
Banco BPM
BIT
STMMI
ST Microelectronics
BIT
MB
Mediobanca Banca di Cred...
BIT
PST
Poste Italiane S.p.a
BIT
A2A
A2A
BIT
LDO
Leonardo
BIT
IP
Interpump
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network